Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development
- PMID: 34176057
- DOI: 10.1007/s11030-021-10257-9
Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development
Erratum in
-
Correction to: Exploration of chalcones and related heterocycle compounds as ligands of adenosine receptors: therapeutics development.Mol Divers. 2022 Aug;26(4):2371. doi: 10.1007/s11030-021-10305-4. Mol Divers. 2022. PMID: 34606074 No abstract available.
Abstract
Adenosine receptors (ARs) are ubiquitously distributed throughout the mammalian body where they are involved in an extensive list of physiological and pathological processes that scientists have only begun to decipher. Resultantly, AR agonists and antagonists have been the focus of multiple drug design and development programmes within the past few decades. Considered to be a privileged scaffold in medicinal chemistry, the chalcone framework has attracted a substantial amount of interest in this regard. Due to the potential liabilities associated with its structure, however, it has become necessary to explore other potentially promising compounds, such as heterocycles, which have successfully been obtained from chalcone precursors in the past. This review aims to summarise the emerging therapeutic importance of adenosine receptors and their ligands, especially in the central nervous system (CNS), while highlighting chalcone and heterocyclic derivatives as promising AR ligand lead compounds.
Keywords: Adenosine receptors; Central nervous system; Chalcone; Heterocycle.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Similar articles
-
Significance of Chalcone Scaffolds in Medicinal Chemistry.Top Curr Chem (Cham). 2024 Jun 27;382(3):22. doi: 10.1007/s41061-024-00468-7. Top Curr Chem (Cham). 2024. PMID: 38937401 Review.
-
Adenosine Receptor Ligands: Coumarin-Chalcone Hybrids as Modulating Agents on the Activity of hARs.Molecules. 2020 Sep 19;25(18):4306. doi: 10.3390/molecules25184306. Molecules. 2020. PMID: 32961824 Free PMC article.
-
Anticancer Active Heterocyclic Chalcones: Recent Developments.Anticancer Agents Med Chem. 2021;21(5):558-566. doi: 10.2174/1871520620666200705215722. Anticancer Agents Med Chem. 2021. PMID: 32628595 Review.
-
Chalcone-inspired rA1 /A2A adenosine receptor ligands: Ring closure as an alternative to a reactive substructure.Chem Biol Drug Des. 2022 Mar;99(3):416-437. doi: 10.1111/cbdd.13999. Epub 2021 Dec 27. Chem Biol Drug Des. 2022. PMID: 34878728
-
Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications.Eur J Med Chem. 2019 Jul 15;174:142-158. doi: 10.1016/j.ejmech.2019.04.032. Epub 2019 Apr 16. Eur J Med Chem. 2019. PMID: 31035237 Review.
Cited by
-
Cyclization of Chalcone Derivatives: Design, Synthesis, In Silico Docking Study, and Biological Evaluation of New Quinazolin-2,4-diones Incorporating Five-, Six-, and Seven-Membered Ring Moieties as Potent Antibacterial Inhibitors.ACS Omega. 2023 Jul 21;8(30):27216-27230. doi: 10.1021/acsomega.3c02478. eCollection 2023 Aug 1. ACS Omega. 2023. PMID: 37546635 Free PMC article.
-
A2B Adenosine Receptor in Idiopathic Pulmonary Fibrosis: Pursuing Proper Pit Stop to Interfere with Disease Progression.Int J Mol Sci. 2023 Feb 23;24(5):4428. doi: 10.3390/ijms24054428. Int J Mol Sci. 2023. PMID: 36901855 Free PMC article. Review.
-
Chalcones as Potential Ligands for the Treatment of Parkinson's Disease.Pharmaceuticals (Basel). 2022 Jul 10;15(7):847. doi: 10.3390/ph15070847. Pharmaceuticals (Basel). 2022. PMID: 35890146 Free PMC article. Review.
-
Significance of Chalcone Scaffolds in Medicinal Chemistry.Top Curr Chem (Cham). 2024 Jun 27;382(3):22. doi: 10.1007/s41061-024-00468-7. Top Curr Chem (Cham). 2024. PMID: 38937401 Review.
References
-
- Feigin VL, Vos T, Abajobir AA et al (2017) Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 16(11):877–897. https://doi.org/10.1016/S1474-4422(17)30299-5 - DOI
-
- Standaert DG, Roberson ED (2011) Treatment of central nervous system degenerative disorders. In: Brunton LL (ed) Goodman & Gilman’s: the pharmacological basis of therapeutics, 12th edn. McGraw-Hill, New York, pp 609–628
-
- Fredholm BB (2014) Adenosine—a physiological or pathophysiological agent? J Mol Med 92(3):201–206. https://doi.org/10.1007/s00109-013-1101-6 - DOI - PubMed
-
- Yuzlenko O, Kiec-Kononowicz K (2006) Potent adenosine A1 and A2A receptors antagonists: recent developments. Curr Med Chem 13(30):3609–3625. https://doi.org/10.2174/092986706779026093 - DOI - PubMed
-
- Zhuang C, Zhang W, Sheng C, Zhang W, Xing C, Miao Z (2017) Chalcone: a privileged structure in medicinal chemistry. Chem Rev 117(12):7762–7810. https://doi.org/10.1021/acs.chemrev.7b00020 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous